Champions Oncology, Inc.
CSBRHealthcare|Biotechnology|US
$4.79
+0.03 (+0.63%)
DCF Value
$4.14
Tangible Book / Share
$0.30
Cash / Share
$0.31
Financials
Financial Snapshot
Market Cap
$66.7M
Enterprise Value
$73.3M
Revenue (TTM)
$60.7M
Net Income (TTM)
-$1.1M
Cash & Investments
$4.4M
Net Cash
-$6.6M
Free Cash Flow (TTM)
-$6.1M
Operating CF (TTM)
-$5.6M
Debt/Equity
2.82
Cash Runway & Burn Rate
Cash on Hand
$4.4M
Quarterly Burn
$1.4M
Monthly Burn
$463.7K
Est. Runway
~3.1 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $3.3M | $856.0K | $3.2M | $8.3M | $4.7M | $9.0M | $10.1M | $2.6M | $9.8M | $4.9M | $4.4M | |
| Operating Cash Flow | -$2.8M | -$1.2M | $1.9M | $2.9M | -$1.7M | $6.5M | $4.0M | -$6.1M | $7.4M | -$4.5M | -$5.6M | |
| Free Cash Flow | -$3.6M | -$2.5M | $1.0M | $685.0K | -$5.0M | $4.1M | $1.1M | -$7.0M | $7.0M | -$5.0M | -$6.1M | |
| Capital Expenditure | -$766.0K | -$1.2M | -$834.0K | -$2.2M | -$3.3M | -$2.4M | -$2.9M | -$836.0K | -$389.0K | -$564.0K | -$573.0K | |
| Financing Cash Flow | $4.3M | $13.0K | $1.2M | $4.4M | $1.2M | $207.0K | $11.0K | -$527.0K | $170.0K | $99.0K | $146.0K |
R&D Spending
R&D (TTM)
$9.3M
R&D Intensity
15.4%
R&D Growth vs Prior
+2.9%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.4M | $20.2M | $27.1M | $32.1M | $41.0M | $49.1M | $53.9M | $50.2M | $56.9M | $59.4M | $60.7M | |
| R&D Expense | $4.3M | $4.4M | $4.8M | $5.9M | $7.2M | $9.4M | $11.5M | $9.5M | $6.8M | $9.1M | $9.3M | |
| R&D % of Revenue | 27.9% | 21.7% | 17.7% | 18.2% | 17.5% | 19.1% | 21.4% | 19.0% | 12.0% | 15.3% | 15.4% | |
| SG&A | $8.2M | $6.6M | $7.7M | $10.9M | $12.0M | $15.5M | $17.2M | $18.1M | $16.9M | $20.5M | $21.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.4M | $20.2M | $27.1M | $32.1M | $41.0M | $49.1M | $53.9M | $50.2M | $56.9M | $59.4M | $60.7M | |
| Cost of Revenue | $9.7M | $10.6M | $14.3M | $17.0M | $21.4M | $23.6M | $29.5M | $29.4M | $28.4M | $30.9M | $30.8M | |
| Gross Profit | $5.7M | $9.7M | $12.8M | $15.1M | $19.6M | $25.5M | $24.3M | $20.8M | $28.6M | $28.5M | $29.9M | |
| R&D | $4.3M | $4.4M | $4.8M | $5.9M | $7.2M | $9.4M | $11.5M | $9.5M | $6.8M | $9.1M | $9.3M | |
| SG&A | $8.2M | $6.6M | $7.7M | $10.9M | $12.0M | $15.5M | $17.2M | $18.1M | $16.9M | $20.5M | $21.8M | |
| Operating Income | -$6.8M | -$1.4M | $270.0K | -$1.9M | $366.0K | $607.0K | -$4.4M | -$6.9M | $4.8M | -$1.1M | -$1.0M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$6.9M | -$1.4M | $231.0K | -$2.0M | $437.0K | $583.0K | -$5.3M | -$7.3M | $4.6M | -$929.0K | -$892.0K | |
| Net Income | -$6.9M | -$1.5M | $128.0K | -$2.1M | $362.0K | $548.0K | -$5.3M | -$7.3M | $4.7M | -$1.2M | -$1.1M | |
| EPS (Diluted) | -0.63 | -0.13 | 0.01 | -0.18 | 0.02 | 0.04 | -0.39 | -0.54 | 0.33 | -0.08 | -0.08 | |
| EBITDA | -$6.6M | -$994.0K | $876.0K | -$761.0K | $1.6M | $2.2M | -$3.0M | -$5.4M | $6.3M | $448.0K | $447.0K | |
| Shares Out. (M) | 10.98 | 11.00 | 14.10 | 11.84 | 14.57 | 14.16 | 13.54 | 13.55 | 14.27 | 13.83 | 13.90 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.3M | $856.0K | $3.2M | $8.3M | $4.7M | $9.0M | $10.1M | $2.6M | $9.8M | $4.9M | $4.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $5.9M | $5.1M | $7.9M | $13.5M | $12.6M | $19.7M | $19.5M | $13.6M | $22.4M | $19.2M | $19.3M | |
| Total Assets | $8.0M | $8.1M | $11.3M | $20.8M | $27.6M | $35.4M | $34.3M | $26.1M | $32.3M | $27.0M | $33.3M | |
| Total Current Liabilities | $7.4M | $7.5M | $8.0M | $12.3M | $11.2M | $17.5M | $21.7M | $21.5M | $23.9M | $19.9M | $18.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $7.6M | $8.1M | $9.0M | $15.7M | $20.2M | $26.3M | $29.7M | $28.0M | $28.6M | $22.9M | $28.8M | |
| Stockholders' Equity | $400.0K | $3.0K | $2.2M | $5.1M | $7.4M | $9.1M | $4.6M | -$1.9M | $3.8M | $3.9M | $3.9M | |
| Retained Earnings | -$69.3M | -$70.8M | -$70.7M | -$72.9M | -$72.5M | -$72.0M | -$77.3M | -$84.6M | -$79.9M | -$81.1M | -$81.5M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8M | -$1.2M | $1.9M | $2.9M | -$1.7M | $6.5M | $4.0M | -$6.1M | $7.4M | -$4.5M | -$5.6M | |
| Capital Expenditure | -$766.0K | -$1.2M | -$834.0K | -$2.2M | -$3.3M | -$2.4M | -$2.9M | -$836.0K | -$389.0K | -$564.0K | -$573.0K | |
| Free Cash Flow | -$3.6M | -$2.5M | $1.0M | $685.0K | -$5.0M | $4.1M | $1.1M | -$7.0M | $7.0M | -$5.0M | -$6.1M | |
| Investing Cash Flow | -$766.0K | -$1.2M | -$834.0K | -$2.2M | -$3.2M | -$2.4M | -$2.9M | -$836.0K | -$389.0K | -$540.0K | -$549.0K | |
| Financing Cash Flow | $4.3M | $13.0K | $1.2M | $4.4M | $1.2M | $207.0K | $11.0K | -$527.0K | $170.0K | $99.0K | $146.0K | |
| Issuance of Stock | $4.3M | $38.0K | $1.5M | $4.5M | $1.4M | $207.0K | $85.0K | $253.0K | $320.0K | $234.0K | $262.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$74.0K | -$634.0K | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$24.0K | -$25.0K | -$262.0K | -$35.0K | -$174.0K | $0.00 | $0.00 | -$146.0K | -$150.0K | -$135.0K | -$116.0K | |
| Stock Based Comp. | $2.7M | $1.0M | $636.0K | $600.0K | $598.0K | $912.0K | $864.0K | $1.1M | $654.0K | $1.2M | $1.8M | |
| Net Change in Cash | $710.0K | -$2.4M | $2.2M | $5.1M | -$3.7M | $4.3M | $1.1M | -$7.5M | $7.2M | -$4.9M | -$6.0M |
Dilution Tracker
Shares Outstanding
14M
5-Year Share Growth
-5.1%
Stock Issuance (TTM)
$262.0K
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 10.98 | 11.00 | 14.10 | 11.84 | 14.57 | 14.16 | 13.54 | 13.55 | 14.27 | 13.83 | 13.90 | |
| Change vs Prior % | — | 0.2% | 28.1% | -16.0% | 23.1% | -2.8% | -4.4% | 0.0% | 5.3% | -3.0% | 0.5% | |
| Stock Issuance | $4.3M | $38.0K | $1.5M | $4.5M | $1.4M | $207.0K | $85.0K | $253.0K | $320.0K | $234.0K | $262.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$74.0K | -$634.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.7M | $1.0M | $636.0K | $600.0K | $598.0K | $912.0K | $864.0K | $1.1M | $654.0K | $1.2M | $1.8M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 37.0% | 47.9% | 47.3% | 47.1% | 47.7% | 51.9% | 45.2% | 41.4% | 50.1% | 48.0% | 49.3% | |
| Operating Margin % | -44.2% | -6.7% | 1.0% | -6.0% | 0.9% | 1.2% | -8.3% | -13.8% | 8.5% | -1.9% | -1.7% | |
| Net Margin % | -44.7% | -7.3% | 0.5% | -6.5% | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% | -2.0% | -1.9% | |
| EBITDA Margin % | -43.1% | -4.9% | 3.2% | -2.4% | 3.8% | 4.5% | -5.6% | -10.8% | 11.0% | 0.8% | 0.7% | |
| FCF Margin % | -23.4% | -12.1% | 3.8% | 2.1% | -12.1% | 8.4% | 2.0% | -13.9% | 12.3% | -8.5% | -10.1% | |
| ROE % | -1721.0% | -49200.0% | 5.7% | -41.0% | 4.9% | 6.0% | -115.1% | 382.3% | 124.6% | -29.8% | -27.9% | |
| ROA % | -85.9% | -18.3% | 1.1% | -10.1% | 1.3% | 1.5% | -15.5% | -27.8% | 14.5% | -4.4% | -3.4% | |
| ROIC % | -1156.0% | -217.7% | 4.6% | -21.2% | 1.8% | 3.0% | -32.3% | -116.2% | 48.6% | -13.3% | -6.8% | |
| R&D / Revenue % | 27.9% | 21.7% | 17.7% | 18.2% | 17.5% | 19.1% | 21.4% | 19.0% | 12.0% | 15.3% | 15.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.8% | 31.3% | 33.7% | 18.7% | 27.8% | 19.7% | 9.7% | -6.9% | 13.5% | 4.4% | |
| Gross Profit | 128.7% | 69.7% | 32.1% | 18.1% | 29.6% | 30.0% | -4.5% | -14.7% | 37.6% | -0.1% | |
| Operating Income | 34.0% | 80.1% | 119.9% | -811.5% | 119.1% | 65.8% | -832.9% | -55.6% | 170.0% | -123.5% | |
| Net Income | 34.1% | 78.6% | 108.7% | -1735.2% | 117.3% | 51.4% | -1073.5% | -36.4% | 164.6% | -125.0% | |
| EPS (Diluted) | 47.5% | 79.4% | 107.0% | -2078.0% | 113.8% | 56.0% | -1107.8% | -38.5% | 161.1% | -124.2% | |
| Operating Cash Flow | 56.0% | 56.8% | 251.9% | 56.0% | -157.9% | 486.5% | -39.1% | -255.2% | 220.4% | -160.5% | |
| Free Cash Flow | 46.8% | 31.9% | 141.9% | -33.4% | -824.4% | 182.9% | -73.7% | -743.9% | 200.3% | -172.0% | |
| R&D Expense | 2.4% | 2.5% | 9.0% | 22.0% | 22.9% | 30.3% | 23.2% | -17.3% | -28.5% | 33.1% | |
| SG&A Expense | -4.6% | -19.2% | 16.5% | 40.4% | 10.8% | 28.8% | 11.3% | 5.2% | -6.9% | 21.2% | |
| Total Assets | 38.7% | 0.8% | 39.5% | 84.2% | 33.0% | 28.2% | -3.0% | -23.8% | 23.8% | -16.6% | |
| Book Value / Share | 36.8% | -106.1% | 8776.4% | 118.2% | 31.3% | 21.9% | -50.3% | -141.0% | 296.6% | 6.5% | |
| Debt | -24.1% | -31.7% | -62.8% | 23637.5% | 152.8% | -1.4% | -9.2% | -13.6% | -17.8% | -26.1% | |
| Diluted Shares | 26.2% | 0.2% | 28.1% | -16.0% | 23.1% | -2.8% | -4.4% | 0.0% | 5.3% | -3.0% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High21.03 / 388.77 / 803.54
P/S1.10
10Y Low / Med / High1.22 / 2.06 / 3.80
P/B17.10
10Y Low / Med / High11.14 / 20.93 / 15882.88
EV/EBITDA163.94
10Y Low / Med / High15.00 / 94.13 / 183.22
EV/Revenue1.21
10Y Low / Med / High1.19 / 2.07 / 3.69
P/FCFAt Loss
10Y Low / Med / High13.96 / 60.77 / 133.48
Intrinsic Value Models (per share)
DCF Value
$4.14
Tangible Book / Share
$0.30
Cash / Share
$0.31
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -4.11 | -33.35 | 803.54 | -42.89 | 388.77 | 185.06 | -12.46 | -8.98 | 21.03 | -74.50 | -60.63 | |
| P/S Ratio | 1.82 | 2.35 | 3.80 | 2.85 | 3.44 | 2.06 | 1.22 | 1.31 | 1.72 | 1.39 | 1.10 | |
| P/B Ratio | 70.25 | 15882.88 | 46.01 | 17.93 | 18.98 | 11.14 | 14.20 | -34.53 | 25.89 | 20.93 | 17.10 | |
| EV/EBITDA | -3.74 | -47.12 | 113.87 | -114.18 | 94.13 | 46.07 | -21.28 | -12.96 | 15.00 | 183.22 | 163.94 | |
| EV/Revenue | 1.61 | 2.31 | 3.69 | 2.70 | 3.55 | 2.07 | 1.19 | 1.41 | 1.65 | 1.38 | 1.21 |
Analyst Estimates & Quality
Altman Z-Score
-0.28
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 |
|---|---|---|
| Revenue | $65.3M | $70.8M |
| Net Income | $1.4M | $0.00 |
| EPS | $0.10 | $0.00 |
| # Analysts (EPS) | 1 | 0 |
Revenue Segments
By Product
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Other Services | $1.4M | $2.2M | $3.0M | — | — | — |
| Personalized Oncology Services | $166.0K | $49.0K | $116.0K | $18.0K | — | — |
| Pharmacology Services | $39.5M | $46.8M | $50.7M | $47.0M | $48.6M | $57.1M |
| Product and Service, Other | — | — | — | $3.1M | $3.7M | $1.5M |
| License and Maintenance | — | — | — | — | $4.7M | — |